Novel oral anticoagulants--issues in clinical practice
Hohmann, C.; Neumann-Haefelin, T.; Radziwill, R.; Benöhr, P.
Medizinische Monatsschrift für Pharmazeuten 38(10) 374-385; Quiz: 387-388
2015
ISSN/ISBN: 0342-9601 PMID: 26731855 Document Number: 680578
The novel oral anticoagulants (NOAC) dabigatran, apixaban, edoxaban and rivaroxaban target either thrombin or factor Xa for the prevention and treatment of thrombosis. A short introduction of the main indications for an oral anticoagulation is followed by the pharmacology of each drug, their effectiveness, selected drug-drug interactions and adverse drug events, especially bleeding. The article represents clinical aspects for the perioperative management, the possibilities for monitoring of each drug, the application in patients with renal impairment as well as different advantages and disadvantages.